Most recent update: Friday, April 3, 2020 - 08:40

Bariatric News - Cookies & privacy policy

You are here


Oral semaglutide vs sitagliptin has superior reductions in HbA1c and weight

Oral semaglutide 7mg and 14mg demonstrated superior HbA1c and body weight reductions compared to Januvia (sitagliptin 100mg), although non-inferiority for oral semaglutide 3mg for HbA1c reductions at 26 weeks was not confirmed.

Semaglutide safe and effective against type 2 diabetes

Semaglutide is safe and effective for the treatment of type 2 diabetes, according to a review by researchers from the Aristotle University of Thessaloniki, Greece. The researchers found that semaglutide is a potent once‐weekly GLP‐1 RA, reducing significantly HbA1c, body weight and systolic blood pressure. However, they noted semaglutide was associated with increased incidence of gastrointestinal adverse events.

semaglutide could help people with obesity lose weight

The compound semaglutide that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight, according to a study by researchers at University of South Carolina. semaglutide has a chemical structure that is very similar to the hormone glucagon-like peptide 1 (GLP-1), which regulates both insulin secretion and appetite. In December, the FDA approved the semaglutide injection Ozempic as a once-weekly adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.

Novo Nordisk gains FDA approval of Ozempic for T2DM

Novo Nordisk has received FDA approval of Ozempic (semaglutide injection) that is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Ozempic, the approved brand name for once-weekly semaglutide in the US, is a glucagon-like peptide 1 (GLP-1) receptor agonist.

Subscribe to RSS - semaglutide